Inyección de acción prolongada de RISPERDAL® CONSTA® (risperidona)

Acerca de la esquizofrenia
Diagnóstico de esquizofrenia
Viviendo con esquizofrenia
Acerca de RISPERDAL CONSTA
Manteniéndose en tratamiento
Centro de noticias
Recursos
Preguntas frecuentes
Also in English
Información completa de prescripción en los EE.UU.
Mapa del sitio
Recursos a nivel mundial
Informe a un amigo(a)
Política de privacidad
Aviso legal
Versión para imprimir
 Tamaño del texto:  S | M |  L
 
 
 
    

Bienvenido a RISPERDALCONSTA.com


RISPERDAL CONSTA es un medicamento para tratar la esquizofrenia. Su eficacia ha sido comprobada usando un novedoso sistema de administración que le proporciona el mismo fármaco que las tabletas de RISPERDAL® (Risperidona), pero en dosis administrada cada dos semanas.



Obtenga más información sobre los efectos secundarios
Obtenga más información sobre los efectos secundarios
Informese sobre los efectos secundarios más frecuentes al tomar RISPERDAL CONSTA.
Obtenga más información.
Preguntas frecuentes
Preguntas frecuentes
Para ver las preguntas frecuentes acerca de RISPERDAL CONSTA, haga clic aquí.
Mensaje de esperanza

Mensaje de esperanza Envie un mensaje de esperanza. Haga clic aquí.
 
 
Suscripción al boletín informativo
Suscripción al boletín informativo
Suscríbase para recibir el boletín informativo sobre la esquizofrenia y su tratamiento.
Folleto para el paciente
Ver y descargar
Folleto para el paciente Folleto de RISPERDAL CONSTA de educación para el paciente. Haga clic aquí.

 


RISPERDAL® (risperidone) and RISPERDAL® CONSTA® (risperidone) are used for the treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION FOR RISPERDAL AND RISPERDAL CONSTA

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL (risperidone) and RISPERDAL CONSTA (risperidone) are not approved for the treatment of patients with dementia-related psychosis.

The most common adverse reactions observed in all clinical trials with RISPERDAL occurring at a rate of at least 10% were somnolence, increased appetite, fatigue, rhinitis, upper respiratory tract infection, vomiting, coughing, urinary incontinence, increased saliva, constipation, fever, tremors, muscle stiffness, abdominal pain, anxiety, nausea, dizziness, dry mouth, rash, restlessness, and indigestion.

The most common side effects that occurred with RISPERDAL CONSTA were sleepiness, restlessness, tremors and muscle stiffness, stomach upset, constipation, dry mouth, feeling tired, and weight increase.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL, RISPERDAL CONSTA, and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL, RISPERDAL CONSTA, and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

RISPERDAL and RISPERDAL CONSTA should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

RISPERDAL, RISPERDAL CONSTA, and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

01RS2005




High blood sugar and diabetes have been reported with RISPERDAL, RISPERDAL CONSTA, and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

Some people taking RISPERDAL or RISPERDAL CONSTA may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional’s dosing instructions, this side effect may be reduced or it may go away over time.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Some medications interact with RISPERDAL or RISPERDAL CONSTA. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid alcohol while taking RISPERDAL or RISPERDAL CONSTA.

Inform your healthcare professional if you are pregnant or if you are planning to get pregnant while taking RISPERDAL or RISPERDAL CONSTA. Do not breast-feed if you are taking RISPERDAL or RISPERDAL CONSTA.

RISPERDAL and RISPERDAL CONSTA may affect your driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL and RISPERDAL CONSTA may affect alertness and motor skills; use caution until the effect of RISPERDAL or RISPERDAL CONSTA is known.

For more information, read the Important Product Information by clicking here.



Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Página principal   Janssen.com   Mapa del sitio    Contáctenos   

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2003 – 2008. Este sitio está publicado por Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., único responsable del contenido. Este sitio está dirigido a residentes de los Estados Unidos.
Esta página fue actualizada por última vez el: